Abstract
Introduction
This study evaluated the efficacy and safety of diquafosol ophthalmic solution (DQS) in soft contact lens (SCL)-related dry eye using artificial tear as a control.
Methods
This study enrolled 26 patients with SCL-related dry eye. DQS and artificial tears (AT) were instilled into the right and left eyes, respectively, with their SCLs on. Dry eye examinations (including tear film breakup time, tear volume, and staining score) were performed and visual function (including contrast sensitivity) was also evaluated before (at baseline) and after treatment (at 4- and 8-week examinations). Subjective symptoms were assessed separately in each eye using a questionnaire on dry eye in contact lens wearers. The results were compared before and after treatment, and between the right eyes treated with DQS (the DQS eye) and the left eyes treated with AT (the AT eye) using the mixed effect model.
Results
Corneal and conjunctival staining scores at 8-week examination were significantly lower than those at baseline in the DQS eye (p = 0.03; p < 0.001, respectively), but no significant changes were observed in the AT eye. Most subjective symptoms improved significantly in both the DQS and AT eyes. However, major subjective symptoms (dryness and blurry vision) improved significantly only in the DQS eye at 8-week examination. Contrast sensitivity at 8-week examination in the DQS eye improved significantly at 12 cycles/degree compared to baseline (p = 0.001) and was significantly better than that in the AT eye (p = 0.03). There were no adverse events related to DQS or AT.
Conclusions
DQS was effective and safe for SCL-related dry eye. DQS also improved contrast sensitivity.
Trial Registration
University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), Identification No. UMIN000024064.
Similar content being viewed by others
References
Tsubota K, Yokoi N, Shimazaki J, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65–76.
Uchino M, Nishiwaki Y, Michikawa T, et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology. 2011;118:2361–7.
Abusharha AA, Pearce EI. The effect of low humidity on the human tear film. Cornea. 2013;32:429–34.
Smith JA, Albietz J, Begley C, et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:93–107.
Vajdic C, Holden BA, Sweeney DF, Cornish RM. The frequency of ocular symptoms during spectacle and daily soft and rigid contact lens wear. Optom Vis Sci. 1999;76:705–11.
Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci. 1997;74:624–31.
Nichols JJ, King-Smith PE. Thickness of the pre-and post-contact lens tear film measured in vivo by interferometry. Investig Ophthalmol Vis Sci. 2003;44:68–77.
Chen Q, Wang J, Tao A, Shen M, Jiao S, Lu F. Ultrahigh-resolution measurement by optical coherence tomography of dynamic tear film changes on contact lenses. Invest Ophthalmol Vis Sci. 2010;51:1988–93.
Craig JP, Willcox MDP, Argueso P, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the contact lens interactions with the tear film subcommittee. Investig Ophthalmol Vis Sci. 2013;54:123–56.
Nichols JJ, King-Smith PE. The effect of eye closure on the post-lens tear film thickness during silicone hydrogel contact lens wear. Cornea. 2003;22:539–44.
Kimball SH, King-Smith PE, Nichols JJ. Evidence for the major contribution of evaporation to tear film thinning between blinks. Investig Ophthalmol Vis Sci. 2010;51:6294–7.
King-Smith PE, Nichols JJ, Nichols KK, Fink BA, Braun RJ. Contributions of evaporation and other mechanisms to tear film thinning and break-up. Optom Vis Sci. 2008;85:623–30.
Guillon M, Maissa C. Contact lens wear affects tear film evaporation. Eye Contact Lens. 2008;34:326–30.
Thai LC, Tomlinson A, Ridder WH. Contact lens drying and visual performance: the vision cycle with contact lenses. Optom Vis Sci. 2002;79:381–8.
Papas EB, Ciolino JB, Jacobs D, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the management and therapy subcommittee. Investig Ophthalmol Vis Sci. 2013;54:183–203.
Calvão-Santos G, Borges C, Nunes S, Salgado-Borges J, Duarte L. Efficacy of 3 different artificial tears for the treatment of dry eye in frequent computer users and/or contact lens users. Eur J Ophthalmol. 2011;21:538–44.
Chapman JM, Cheeks L, Green K. Interactions of benzalkonium chloride with soft and hard contact lenses. Arch Ophthalmol. 1990;108:244–6.
Hosoya K, Ueda H, Kim KJ, Lee VH. Nucleotide stimulation of Cl-secretion in the pigmented rabbit conjunctiva. J Pharmacol Exp Ther. 1999;291:53–9.
Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.
Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K, Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.
Takamura E, Tsubota K, Watanabe H, Ohashi Y, Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.
Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol. 2013;57:440–6.
Ohashi Y, Munesue M, Shimazaki J, et al. Long-term safety and effectiveness of diquafosol for the treatment of dry eye in a real-world setting: a prospective observational study. Adv Ther. 2020;37:707–17.
Shigeyasu C, Yamada M, Akune Y, Fukui M. Diquafosol for soft contact lens dryness: clinical evaluation and tear analysis. Optom Vis Sci. 2016;93:973–8.
Yamaguchi M, Nishijima T, Shimazaki J, et al. Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study. Clin Ophthalmol. 2015;9:2251–6.
Miyake G, Ota I, Miyake K, Zako M, Iwaki M. Effects of topical diquafosol pretreatment on intraoperative corneal wetting. J Cataract Refract Surg. 2014;40:1682–8.
Whittaker SG, Lovie-Kitchin J. Visual requirements for reading. Optom Vis Sci. 1993;70:54–65.
Crossland MD, Culham LE, Rubin GS. Predicting reading fluency in patients with macular disease. Optom Vis Sci. 2005;82:11–7.
Marron JA, Bailey IL. Visual factors and orientation-mobility performance. Am J Optom Physiol Opt. 1982;59:413–26.
Owsley C, Ball K, McGwin G Jr, et al. Visual processing impairment and risk of motor vehicle crash among older adults. JAMA. 1998;279:1083–8.
Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol. 2002;133:350–7.
Applegate RA, Howland HC, Sharp RP, Cottingham AJ, Yee RW. Corneal aberrations and visual performance after radial keratotomy. J Refract Surg. 1998;14:397–407.
Dogru M, Ishida K, Matsumoto Y, et al. Strip meniscometry: a new and simple method of tear meniscus evaluation. Investig Ophthalmol Vis Sci. 2006;47:1895–901.
Lemp MA. Report of the National Eye Institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.
Nichols JJ, Mitchell GL, Nichols KK, Chalmers R, Begley C. The performance of the Contact Lens Dry Eye Questionnaire as a screening survey for contact lens-related dry eye. Cornea. 2002;21:469–75.
Chalmers RL, Begley GG, Moody K, Hickson-Curran SB. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. Optom Vis Sci. 2012;89:1435–42.
Yokoi N, Georgiev GA. Tear film-oriented diagnosis and tear film-oriented therapy for dry eye based on tear film dynamics. Investig Ophthalmol Vis Sci. 2018;59(14):DES3–DES2.
Nagahara Y, Koh S, Nishida K, Watanabe H. Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses. Clin Ophthalmol. 2015;9:1029–31.
Nagahara Y, Koh S, Oshita Y, et al. Diquafosol ophthalmic solution increases pre- and postlens tear film during contact lens wear in rabbit eyes. Eye Contact Lens. 2017;43:378–82.
Koh S, Maeda N, Hirohara Y, et al. Serial measurements of higher-order aberrations after blinking in patients with dry eye. Investig Ophthalmol Vis Sci. 2008;49:133–8.
Koh S, Maeda N, Ikeda C, et al. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol. 2014;92:e671-675.
Kwon M, Legge GE. Spatial-frequency requirements for reading revisited. Vis Res. 2012;62:139–47.
Koh S, Maeda N, Ikeda C, et al. The effect of ocular surface regularity on contrast sensitivity and straylight in dry eye. Investig Ophthalmol Vis Sci. 2017;58:2647–51.
Acknowledgements
We wish to express our gratitude to the physicians and staff at the medical institutes that participated in the study.
Funding
Sponsorship and article processing charges, including the journal’s Rapid Service Fees, for this study were funded by Santen Pharmaceutical Co., Ltd., Osaka, Japan.
Medical Writing and Editorial Assistance
We would like to thank Editage (http://www.editage.com) for English language editing. The source of funding for the assistance provided by Editage was funded by Santen Pharmaceutical Co., Ltd., Osaka, Japan.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authorship Contributions
Conceptualization: Tomohiro Ogami, Hiroki Asano, Takahiro Hiraoka, and Yoshiaki Yamada. Methodology: Tomohiro Ogami, Hiroki Asano, Takahiro Hiraoka, and Yoshiaki Yamada. Investigation: Tomohiro Ogami and Hiroki Asano. Data curation: Tomohiro Ogami and Hiroki Asano. Data analysis: Tomohiro Ogami, Hiroki Asano, Takahiro Hiraoka, and Yoshiaki Yamada. Writing–original draft preparation: Yoshiaki Yamada. Writing–review and editing: Tomohiro Ogami, Hiroki Asano, Takahiro Hiraoka, and Tetsuro Oshika. Supervision: Takahiro Hiraoka and Tetsuro Oshika. All authors read and approved the final manuscript.
Disclosures
Tomohiro Ogami has received research funding from Santen Pharmaceutical Co., Ltd. and has received lecture fees from Santen Pharmaceutical Co., Ltd. Current affiliation is Miyakubo Eye Clinic, Gunma, Japan. Hiroki Asano has received research funding from Santen Pharmaceutical Co., Ltd. and has received lecture fees from Santen Pharmaceutical Co., Ltd. Current affiliation is Tsuchiura Kyodo General Hospital, Ibaraki, Japan. Takahiro Hiraoka has received lecture fees from Santen Pharmaceutical Co., Ltd. Yoshiaki Yamada is an employee of Santen Pharmaceutical Co., Ltd. Tetsuro Oshika has received research funding from Santen Pharmaceutical Co., Ltd. and has received lecture fees from Santen Pharmaceutical Co., Ltd. The authors have no other conflicts of interest to declare.
Compliance with Ethics Guidelines
All participants were provided with a full explanation about the study and they provided written informed consent. This study followed the tenets of the Declaration of Helsinki, and was approved by the institutional review board and the ethics committee at each study site (namely the Ibaraki Seinan Medical Center Hospital ethics committee and Namegata District Medical Center ethics committee, reference number; 16-2).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogami, T., Asano, H., Hiraoka, T. et al. The Effect of Diquafosol Ophthalmic Solution on Clinical Parameters and Visual Function in Soft Contact Lens-Related Dry Eye. Adv Ther 38, 5534–5547 (2021). https://doi.org/10.1007/s12325-021-01910-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-021-01910-8